Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts

Clinical Infectious Diseases

Volumn 56, Issue 6, 2013, Pages 888-897

  Touloumi, Giota ^a   Pantazis, Nikos ^a   Pillay, Deenan ^b   Paraskevis, Dimitrios ^a   Chaix, Marie Laure ^c,d   Bucher, Heiner C ^e   Kücherer, Claudia ^f   Zangerle, Robert ^g   Kran, Anne Marte Bakken ^h   Porter, Kholoud ⁱ  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f ROBERT KOCH INSTITUTE   (Germany)

^g UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

CD4 decline; HIV 1 subtype; natural history; set point

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEATH; EUROPE; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; GENOTYPE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874789824     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1000     Document Type: Article

References (31)

1. Geretti AG. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7.
2. Tebit DM, Nankya I, Arts NE, Gao Y. HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev 2007; 9:75-87.
3. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-5.
4. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979-90.
5. Kanki PJ, Hamel DJ, Sankale J-L, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179: 68-73.
6. Neilson JR, John GC, Carr JK, et al. Subtypes of human immunodeficiency virus type 1 and disease progression among women in Nairobi, Kenya. J Virol 1999; 73:4393-403.
7. Kaleebu P, Ross A, Morgan D, et al. Relationship between HIV-1 env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15:293-9.
8. Laurent C, Bourgeois A, Faye MA, et al. No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02-AG strain and patients not infected with CRF02-AG, in western and West-Central Africa: a four-year prospective multicenter study. J Infect Dis 2002; 186:486-92.
9. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-52.
10. Sarr AD, Eisen G, Gueye-Ndiaye A, et al. Viral dynamics in primary HIV-1 infection in Senegal, West Africa. J Infect Dis 2005; 191:1460-7.
11. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-52.
12. Giuliani M, Montieri S, Palamara G, et al. Non-B HIV type 1 subtype among men who have sex with men in Rome, Italy. AIDS Res Hum Retrovirus 2009; 25:157-64.
13. González-Alba JM, Holguín A, Garcia R, et al. Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis. J Virol 2011; 85:10755-63.
14. Paraskevis D, Magiorkinis E, Magiorkinis G, et al. Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. J Infect Dis 2007; 196:1167-76.
15. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1:224-31.
16. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-800.
17. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
18. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. Stat Med 1999; 18:1215-33.
19. Pantazis N, Touloumi G. Analyzing longitudinal data in the presence of informative drop-out: the jmre1 command. Stata J 2010; 10:226-51.
20. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-80.
21. Kiwanuka N, Robb M, Laeyendecker O, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr 2010; 54:180-4.
22. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13:4.
23. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J. Pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombinant patterns, and common ancestry for subtypes B and D. J Virol 1997; 71:6348-58.
24. Njai H, Gali Y, Vanham G, et al. The predominance of HIV-1 circulating recombinant form 02 (CRF02-AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006; 3:40-6.
25. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. JID 2008; 197:707-13.
26. Tek ONg, Lin L, Laeyendecker O, et al. Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01-AE infected seroconverters in Singapore. PLoS One 2011; 6: e15738.
27. Mori M, Sriwanthana B, Wichukchinda N, et al. Unique CRF01-AE CTL epitopes associated with lower HIV-viral load and delayed disease progression in a cohort of HIV-infected Thais. PLoS One 2011; 6: e22680.
28. Novitsky V, Ndung'u T, Wang R, et al. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 C subtype infection. AIDS 2011; 25:1515-22.
29. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5:e12598.
30. Muller V, von Wyl V, Yerly S, et al. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort study. AIDS 2009; 23:1269-76.
31. Pantazis N, Morrison C, Amornkul PN, et al. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One 2012; 7:e32369.